MRNA vs VIR
MRNA: Moderna is an unprofitable mRNA vaccine and therapeutic company pivoting from peak COVID revenues with a diversified pipeline facing intense competition and declining sales. VIR: Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking technologies.
Side-by-side fundamentals
| Metric | MRNA | VIR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $58.07 | $9.35 | |
| Market cap as of 2026-07-23 | $22.9B | $1.6B | |
| Net margin as of 2026-07-23 | -143.6% | -638.9% | MRNA higher |
| Gross margin as of 2026-07-23 | +35.0% | +100.0% | VIR higher |
| Operating margin as of 2026-07-23 | -153.3% | -699.2% | MRNA higher |
| ROE as of 2026-07-23 | -36.7% | -49.3% | MRNA higher |
| ROA as of 2026-07-23 | -26.6% | -38.7% | MRNA higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.00 | VIR lower |
| Revenue growth (YoY) as of 2026-07-23 | -30.0% | -7.6% | VIR higher |
| Revenue CAGR (3y) SEC XBRL | -53.4% | -65.1% | MRNA higher |
| Beta as of 2026-07-23 | 0.88 | 1.60 | |
| 1-year return as of 2026-07-22 close | +77.4% | +70.7% | MRNA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.